US Patent 7189745 Compounds
Patent 7189745 was granted and assigned to Smithkline Beecham Limited on March, 2007 by the United States Patent and Trademark Office.
All edits
Edits on 1 Sep, 2023
Golden AI
Edits made to:
Article (+268 characters)
Article
Patent abstract
The present invention is directed to novel compounds of Formula (I) for use in the treatment of diseases, in a mammal, in which inappropriate, excessive or undesirable angiogenesis has occurred and/or where excessive Tie2 receptor activity has occurred.
Edits on 14 Jul, 2023
Golden AI
Edits made to:
Infobox (+1/-1 properties)
US Patent 07189745 Compounds US Patent 7189745 Compounds
Infobox
Patent Number
0718974500
Patent Number
718974500
Edits on 26 May, 2023
Golden AI
Edits made to:
Infobox (-1 properties)
Infobox
Official Website
Edits on 29 Apr, 2023
Golden AI
Infobox
Is a
Current Assignee
Patent Jurisdiction
Patent Number
071897450
Date of Patent
March 13, 2007
0Patent Application Number
101300180
Date Filed
November 20, 2000
0Official Website
Patent Primary Examiner
Edits on 26 Sep, 2022
Golden AI
Infobox
Is a
Current Assignee
Patent Jurisdiction
Patent Number
071897450
Date of Patent
March 13, 2007
0Patent Application Number
101300180
Date Filed
November 20, 2000
0Official Website
Patent Primary Examiner
Edits on 8 Jun, 2022
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Website URL
Edits on 20 Nov, 2021
Golden AI
Edits made to:
Infobox (+8 properties)
US Patent 07189745 Compounds
Infobox
Is a
Current assignee
Patent jurisdiction
Patent number
07189745
Date of patent
March 13, 2007
Patent application number
10130018
Date Filed
November 20, 2000
Patent primary examiner
Find more entities like US Patent 7189745 Compounds
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
